Compare BDTX & RDZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BDTX | RDZN |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 87.7M |
| IPO Year | 2020 | 2021 |
| Metric | BDTX | RDZN |
|---|---|---|
| Price | $1.38 | $0.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $11.00 | $5.00 |
| AVG Volume (30 Days) | ★ 766.3K | 297.2K |
| Earning Date | 11-10-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.71 | 72.12 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $55,021,792.00 |
| Revenue This Year | N/A | $41.04 |
| Revenue Next Year | N/A | $78.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.21 |
| 52 Week Low | $1.39 | $0.94 |
| 52 Week High | $3.97 | $2.56 |
| Indicator | BDTX | RDZN |
|---|---|---|
| Relative Strength Index (RSI) | 34.73 | 37.67 |
| Support Level | N/A | N/A |
| Resistance Level | $1.94 | $1.27 |
| Average True Range (ATR) | 0.14 | 0.10 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 0.84 | 22.87 |
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express. Geographically, the company operates in India, United States of America, United Kingdom, and China. It generates maximum revenue form India.